|
Gene: TMPRSS15 |
Gene summary for TMPRSS15 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TMPRSS15 | Gene ID | 5651 |
Gene name | transmembrane serine protease 15 | |
Gene Alias | ENTK | |
Cytomap | 21q21.1 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P98073 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5651 | TMPRSS15 | Pat01-B | Human | Stomach | GC | 6.27e-43 | 8.77e-01 | 0.5754 |
5651 | TMPRSS15 | Pat03-B | Human | Stomach | GC | 1.62e-38 | 1.10e+00 | 0.3693 |
5651 | TMPRSS15 | Pat17-B | Human | Stomach | GC | 8.97e-18 | 5.64e-01 | 0.3109 |
5651 | TMPRSS15 | SIM_1 | Human | Stomach | SIM | 3.98e-11 | 4.84e-01 | 0.3573 |
5651 | TMPRSS15 | SIM_2 | Human | Stomach | SIM | 8.72e-11 | 3.39e-01 | 0.3139 |
5651 | TMPRSS15 | SIM_4 | Human | Stomach | SIM | 7.38e-15 | 5.89e-01 | 0.2664 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMPRSS15 | SNV | Missense_Mutation | c.329N>C | p.Arg110Thr | p.R110T | P98073 | protein_coding | tolerated(0.06) | benign(0.018) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
TMPRSS15 | SNV | Missense_Mutation | c.1517T>A | p.Leu506His | p.L506H | P98073 | protein_coding | tolerated(0.55) | possibly_damaging(0.45) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMPRSS15 | SNV | Missense_Mutation | c.158G>C | p.Gly53Ala | p.G53A | P98073 | protein_coding | tolerated(0.11) | benign(0.009) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMPRSS15 | SNV | Missense_Mutation | c.977G>A | p.Gly326Asp | p.G326D | P98073 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMPRSS15 | SNV | Missense_Mutation | novel | c.1885N>A | p.Ala629Thr | p.A629T | P98073 | protein_coding | deleterious(0.04) | probably_damaging(0.936) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMPRSS15 | SNV | Missense_Mutation | c.65N>T | p.Ala22Val | p.A22V | P98073 | protein_coding | tolerated(0.28) | benign(0.007) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMPRSS15 | SNV | Missense_Mutation | c.329N>C | p.Arg110Thr | p.R110T | P98073 | protein_coding | tolerated(0.06) | benign(0.018) | TCGA-D8-A27I-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimycin+cyclophosphamide | SD | |
TMPRSS15 | SNV | Missense_Mutation | c.236N>T | p.Ser79Leu | p.S79L | P98073 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
TMPRSS15 | SNV | Missense_Mutation | c.2581N>A | p.Glu861Lys | p.E861K | P98073 | protein_coding | deleterious(0.03) | benign(0.006) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | |
TMPRSS15 | SNV | Missense_Mutation | novel | c.1835N>G | p.Met612Arg | p.M612R | P98073 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | THONZONIUM BROMIDE | THONZONIUM BROMIDE | ||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | US9024044, 62 | |||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | CALMIDAZOLIUM CHLORIDE | CALMIDAZOLIUM CHLORIDE | ||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | NSC-60340 | CHEMBL1534034 | ||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | US9024044, 3 | |||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | US9346821, B-13 | |||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | US8609715, A-1 | |||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | US8609715, A-26 | |||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | GNF-PF-254 | CHEMBL461579 | ||
5651 | TMPRSS15 | PROTEASE, DRUGGABLE GENOME, ENZYME | US8609715, B-61 |
Page: 1 2 |